Innovative Developments in Biologics from Seismic Therapeutic
Today, Seismic Therapeutic, Inc., a pioneering machine learning immunology company, announced groundbreaking advancements demonstrating its IMPACT platform's broad capabilities for crafting novel biologic medicines. Utilizing innovative machine learning techniques, Seismic has effectively developed S-1117, an engineered pan-IgG protease designed for chronic administration. This marks a significant milestone as Seismic illustrates its ability to extend these methods to create various biologic modalities beyond just pan-IgG proteases.
IMPACT Platform: A Fusion of Technologies
The IMPACT platform cleverly integrates machine learning with cutting-edge methodologies in structural biology, protein engineering, and immunology. This integration allows for the parallel optimization of multiple properties of novel biologic therapies, which is quite revolutionary in the industry. Seismic has developed proprietary algorithms specifically designed to enhance developability, modulate functional capabilities, and reduce immunogenicity, significantly accelerating the development of biotherapeutics.
Expert Insights on IMPACT Innovations
During a recent oral presentation at the PEGS Europe Protein and Antibody Engineering Summit, Ryan Peckner, PhD, Director and Head of Machine Learning at Seismic Therapeutic, shared insightful highlights from the company's latest research. This includes the original application of the IMPACT platform, where a combination of in silico design and wet lab validation led to the creation of S-1117, effectively minimizing both T cell and B cell epitopes to prevent anti-drug antibody generation while maintaining its stability and activity.
Broader Applications of the IMPACT Platform
Seismic’s innovations also extend to new applications within the IMPACT platform, as highlighted by their success in engineering specificity in proteases. They showcased the first instance of creating a selective IgE protease, which was accomplished through an ingenious multi-objective optimization process in just one design round. This included improving both the activity and stability of the protease.
Future Prospects for Biologic Therapies
As the company continues to explore new horizons, the potential of their IMPACT platform to design novel therapeutic interventions is vast. Seismic is actively pursuing rapid advancements in its lead drug candidates, including S-1117 and S-4321, a dual-cell bidirectional PD-1 antibody agonist, which are anticipated to enter clinical trials early next year. Dr. John Sundy, Chief Medical Officer and Head of R&D at Seismic Therapeutic, emphasized the importance of these advancements, stating how they fortify their platform as a productive engine for creating diverse biologic therapies. These innovations are designed not only to optimize function and reduce immunogenicity but also to enhance the overall drug-like properties of these therapies.
About Seismic Therapeutic
Seismic Therapeutic is revolutionizing the biotechnology landscape by leveraging machine learning to transform the development of immunology therapies. This innovative company is situated within the vibrant Boston biotechnology hub and is underpinned by a robust syndicate of life sciences investors. Seismic is proud to offer a preclinical pipeline filled with best-in-class and first-in-class biologics, carefully developed through its IMPACT platform, aimed at combating various autoimmune diseases.
For additional insights and details, visit their official website and keep updated through their social media channels.
Frequently Asked Questions
What is the IMPACT platform used for?
The IMPACT platform is designed to create novel biologic medicines using machine learning, optimizing various therapeutic properties simultaneously.
What significance does S-1117 have?
S-1117 is an engineered pan-IgG protease aimed at chronic administration, showcasing the capabilities of the IMPACT platform in drug development.
Who presented the recent findings on the IMPACT platform?
Ryan Peckner, PhD, Director and Head of Machine Learning at Seismic Therapeutic, presented the findings during the PEGS Europe Summit.
How does Seismic ensure the effectiveness of their therapies?
Seismic employs machine learning algorithms to predict and eliminate immunogenic epitopes while maintaining the essential attributes required for biologic drugs.
What are the future plans for Seismic Therapeutic?
Seismic Therapeutic aims to advance its candidates into clinical trials and continue enhancing its IMPACT platform for broader applications in autoimmune disease therapies.
